

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-18. (Cancelled)

19. (Previously Presented) A method for treating lymphoma or leukemia in a mammal comprising administering to the mammal a therapeutically effective amount of a variant of a parent antibody which binds CD20 and comprises an Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively than the parent antibody and comprises at least one amino acid modification in the Fc region.

20. (Previously Presented) The method of claim 19 wherein the variant comprises a variant human IgG1 Fc region comprising substitutions at positions 298, 333 and 334 thereof.